Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Illumina, Inc. ILMN
$207.90
-$0.31 (-0.15%)
На 18:00, 12 мая 2023
+78.72%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
32726700000.00000000
-
week52high
258.07
-
week52low
173.45
-
Revenue
4584000000
-
P/E TTM
-7
-
Beta
1.18166000
-
EPS
-27.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
25 апр 2023 г. в 21:00
Описание компании
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Neutral | 25 авг 2022 г. | |
| UBS | Neutral | Neutral | 17 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 12 авг 2022 г. |
| Stifel | Buy | Buy | 12 авг 2022 г. |
| Evercore ISI Group | Outperform | In-Line | 28 сент 2022 г. |
| SVB Leerink | Outperform | Market Perform | 04 окт 2022 г. |
| Barclays | Underweight | Underweight | 30 сент 2022 г. |
| Piper Sandler | Overweight | Overweight | 14 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 ноя 2022 г. |
| Credit Suisse | Neutral | Neutral | 04 ноя 2022 г. |
| RBC Capital | Outperform | 07 дек 2022 г. | |
| Scotiabank | Sector Perform | 05 янв 2023 г. | |
| OTR Global | Positive | Mixed | 20 дек 2022 г. |
| Citigroup | Sell | Neutral | 12 дек 2022 г. |
| Canaccord Genuity | Buy | Buy | 17 янв 2023 г. |
| Argus Research | Hold | Buy | 25 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hoyt Aimee L | D | 2796 | 871 | 09 янв 2023 г. |
| TOUSI SUSAN H | D | 38662 | 500 | 06 янв 2023 г. |
| TOUSI SUSAN H | D | 39162 | 500 | 06 дек 2022 г. |
| Aravanis Alexander | D | 2857 | 361 | 08 ноя 2022 г. |
| Hoyt Aimee L | D | 3667 | 1045 | 07 ноя 2022 г. |
| TOUSI SUSAN H | D | 40112 | 500 | 07 ноя 2022 г. |
| Hoyt Aimee L | D | 3418 | 1294 | 07 ноя 2022 г. |
| Ericksen Scott D | D | 6288 | 213 | 05 ноя 2022 г. |
| Reeves Kathryne Gambrell | D | 4184 | 212 | 05 ноя 2022 г. |
| TOUSI SUSAN H | D | 40612 | 721 | 05 ноя 2022 г. |
Новостная лента
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics
The Motley Fool
06 мая 2023 г. в 08:00
Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.
Why Illumina Fell 11.6% in April
The Motley Fool
06 мая 2023 г. в 07:24
Illumina announced a downbeat set of earnings for its fiscal 2023 first quarter. The company received more than 200 orders for its new NovaSeq X instrument from customers in almost 30 countries.
Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
MarketBeat
03 мая 2023 г. в 07:24
The phrase, “I'm from the government and I'm here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. NASDAQ: ILMN, which specializes in DNA sequencing, government meddling could actually end up helping shareholders.
Icahn Writes Another Open Letter to Illumina Shareholders
GuruFocus
02 мая 2023 г. в 18:20
Sunny Isles Beach, Florida, May 1, 2023 — Today, Carl C. Icahn released the following open letter to the shareholders of Illumina, Inc. ( ILMN , Financial).
Illumina: Icahn's nominees ‘unqualified'
Market Watch
01 мая 2023 г. в 15:21
Illumina Inc. ILMN said Monday that activist investor Carl Icahn's board nominees are “unqualified,” urging shareholders to reject all three of Icahn's nominees and instead support its “highly qualified” nominees. That's the latest salvo between the genomics company and Icahn, who earlier Monday issued the second letter in as many business days to Illumina investors, saying that Chief Executive Francis de Souza and “protectors” seem “dead set on destroying the company.